Business
Med BioGene announces futher promising results on the diagnostic value of its lymphoma genetic biomarkers
Med BioGene announces futher promising results on the diagnostic value of its lymphoma genetic biomarkers.
About this update from Many Bright Ideas Technologies Inc
[{"type":"text","content":"\n\n\n\nVANCOUVER, Feb. 1 /CNW/ - Med BioGene Inc. (TSX Venture: MBI), an\nemerging biotechnology company developing genetic biomarkers for use in\nimproving diagnosis, prognosis and treatment decisions for patients suffering\nfrom certain cancers and cardiovascular disease, is pleased to announce the\nresults of its latest pre-clinical studies involving its Gene Expression\nProfiling System(TM) for diagnosing lymphoma.\n\n\n110 RNA samples derived from human lymphoma tissues, representing the\nseven major subtypes of lymphoma, were analyzed utilizing a 10-fold\ncross-validation approach. Using MBI's genetic biomarkers of between 50 and\n100 genes per subtype, the Gene Expression Profiling System(TM) achieved an\naverage accurate prediction rate of 88% in diagnosing the various lymphoma\nsubtypes against other lymphoma subtypes. According to the accuracy data\ncompiled, the median specificities for diagnosing the various subtypes\naveraged 97%, whereas the median sensitivities averaged 86%.\n\n\nLymphoma is a general term for a group of cancers that originate in the\nlymphatic system. In Canada and the United States, lymphoma is the sixth most\ncommon cancer among males and the fifth most common cancer among females.\nApproximately 56% of all blood cancers are lymphomas and approximately 73,000\nCanadians and Americans will be diagnosed with lymphoma in 2007.\n\n\n\"We are very pleased with these results and are enthusiastic about the\nprospects of our Gene Expression Profiling System(TM) becoming a novel tool\nfor the diagnosis of lymphoma. In comparison to the current method of\ndiagnosing lymphoma, we expect our Gene Expression Profiling System(TM) to be\nfaster, less expensive and more accurate,\" stated Erinn Broshko, Chief\nExecutive Officer of MBI.\n\n\nAbout Med BioGene\n\n\nMBI is a biotechnology company with advanced research and development in\ngene expression technology. MBI intends to utilize its expertise in gene\nexpression to identifying those genes, known as \"biomarkers,\" which mark the\npresence of various diseases. These biomarkers will be used as an effective\ntool for accurate and rapid disease diagnosis and to unlock innovation in\ntherapeutic development and treatment. With a robust set of qualified\nbiomarkers, disease diagnosis will be quicker, less invasive and more accurate\nand the safety of new the...